Cosmo Pharmaceuticals NV (OTCPK:CMOPF)
$ 66.9252 0 (0%) Market Cap: 1.14 Bil Enterprise Value: 1.01 Bil PE Ratio: 15.34 PB Ratio: 2.13 GF Score: 84/100

Full Year 2018 Cosmo Pharmaceuticals NV Earnings Call Transcript

Mar 29, 2019 / 09:00AM GMT
Release Date Price: $84.85
Operator

Ladies and gentlemen, welcome to the Cosmo Pharmaceuticals Full Year Results 2018 Conference Call. I'm Andrei, Chorus Call operator. (Operator Instructions) The conference is being recorded. (Operator Instructions) The conference must not be recorded for publication or broadcast.

At this time, it's my pleasure to hand over to management team of Cosmo Pharmaceuticals. You will be now joined to the conference room.

Alessandro E. Della ChÃ
Cosmo Pharmaceuticals N.V. - CEO & Executive Director

Good morning, and thank you for being here at our full year report presentation for the year 2018. Let me state one thing, which we think is nice and should be taken as a good thing, Cosmo's got now 3 approved products that comes from the same MMX technology. We started with Lialda, then we went further with Uceris and now finally, Aemcolo, our new antibiotic, has been approved, and we are quite proud of this achievement. We've been trying to understand if there are actually companies that have 3 or more products approved with the very same technology, and we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot